Quantum Phar. Share Discussion Threads

[a2584728] 15/8/2017 17:28

Thanks. We should rise to 110p from now may take 3. Months though

[r ball] 15/8/2017 16:49

Low liquidity too.

[ayl30] 15/8/2017 16:49

Stock overhang clearing perhaps

[werewolfie] 15/8/2017 16:39

Any thoughts as to why the share price is increasing? New focused strategy paying off, entering foreign markets, closing Nupharm and selling Biodose all contributing

[hazl] 15/8/2017 16:08

WELL WELL WELL !

[aishah] 15/8/2017 16:05

Hope this is the start of a sustained recovery here.

[ayl30] 15/8/2017 16:00

A258728 - you were right then!

[paleje] 15/8/2017 15:59

should've bypassed the watchlist:)

[ayl30] 15/8/2017 15:39

ello, ello - shot up in price

[a2584728] 09/8/2017 09:24

I expect the share price to increase significantly once the market has digested and understood the huge potential here and at less than 60p a share the upside is massive. Imho of course

[paleje] 09/8/2017 08:28

Thanks much appreciated, hadn't researched, just spotted the TU, going on watchlist.

[cottoner] 09/8/2017 08:23

Paleje - From Final results RNS on may 3rd 2017.


International opportunities

Our product pipeline holds significant value potential. In the UK market, the Group is well-established due to its existing infrastructure and commercial relationships built through our market-leading Specials division. We also have extensive experience and understanding of the UK's development and regulatory approval process as governed by the MHRA through the activities of our Niche division. Our strategic position in the UK is therefore strong.

We are currently seeking to realise the potential of our product portfolio beyond the UK and extend our reach into other geographies by broadening our network of international commercial partnerships. These partnerships will seek to emphasise both export and localised manufacture together with distribution opportunities to secure market access without the need to establish our own local presence.

[r ball] 09/8/2017 08:23

Pj: not really. Colonis is based in Greece anyway.

[paleje] 09/8/2017 08:02

Is the talk of international expansion a new thing? I don't hold presently but the TU sounds confident.

[kemche] 09/8/2017 08:00

Progressing well.

[hazl] 09/8/2017 07:59

RB It is about the future with shares.

[hazl] 09/8/2017 07:59

AH.
Significant improvement in financial performance....
likely to go down well,I would have thought.

[r ball] 09/8/2017 07:46

Yup. I don't expect much reaction. Give it another year.

[ayl30] 09/8/2017 07:06

Positive rns this am in my view

[r ball] 08/8/2017 20:48

Treading water. Up 2p

[ali47fish] 08/8/2017 15:44

so what poeple think we should expect from the update tomorrow?

[rivaldo] 08/8/2017 12:40

New interview with the CEO:



Extracts:

"Quantum Pharma 'fundamentally successful' in simplifying strategy, says chief executive"

"Quantum Pharma’s new business model has been hailed as a “fundamental success” by chief executive Chris Rigg, three months after he closed the company’s struggling NuPharm division."

"Mr Rigg said that Quantum’s effort to focus its business is now paying off.

Speaking to The Journal Mr Rigg said: “The position that the business brought to float was the ability to convert unlicensed medicines to licensed. It then acquired NuPharm.

“It was the business I closed, and it was a business that was failing. It was acquired for the right strategic intent but it was failing.

“Part of what I have done is to focus and simplify the business.

“When you license a product we bring it to market at a lower price than the unlicensed medicine. We can do that as we get a higher market share and manufacture it in bulk.

“The aim is to drive into the future the benefits of the license programme to lower prices in the NHS.”

Under the renewed strategy Quantum is focusing on its core business. This is largely the supply of unlicensed medications – known as specials – and the creation of licensed products through its Colonis arm.

With its network of pharmacies across the UK, Quantum is a market leader in supplying adapted medicines to the market. This process can involve making liquid versions of pills or changing the flavour of medication.

One of the key areas for growth for the firm is Colonis and its licensing division. Once a drug successfully attains a UK license the business involves becomes the only one able to distribute the medication to pharmacies. This gives its a major market advantage.

As part of the new model Mr Rigg has appointed new management teams to oversee its divisions, including Colonis.

“From a control perspective it allows you to focus,” said Rigg. “You can change and make people accountable.”

Despite writing off £13.7m as a result of the NuPharm sale, Mr Rigg said investors reacted well to the renewed focus on its core business. The company’s share price reflected his optimism, and following the closure of NuPharm, Quantum’s share price soared from 43p to 60p over seven days. The price has since levelled off and at the time of writing sits at 55.25p."

[rivaldo] 27/7/2017 12:26

Interesting local press coverage yesterday:



Extract:

"26th July
Burnopfield business says partnerships can help it grow industry presence

A DRUGS company is pushing ahead with plans to increase its international standing, The Northern Echo can reveal.

Quantum Pharma is assessing potential partners to grow around the world....

.....However, Gerard Murray, chief financial officer, told the Echo that the business, which provides work for hundreds of staff, was moving on from its difficulties, with international links on the agenda.

He said: “This is a UK-centric business because we develop products with the UK regulator.

“The idea would be to look for the right partners in a number of territories where we could introduce products.

“We are at the start of that but we have a list and are working to identify partners that could potentially be of benefit.

“It would leverage what we have already got and build on what we have developed and what we are developing.”

Mr Murray also said the firm’s simplified business model will help its progress.

He added: “When you get that, you can identify and manage opportunities and any problems much more quickly.”